BPI-421286 / Betta Pharma - LARVOL DELTA

BPI-421286: A highly potent small molecule inhibitor targeting KRASG12C mutation (AACR 2022) - "Combining BPI-421286 with several targeted agents, including a SHP2 inhibitor BPI-442096 and a CDK4/6 inhibitor BPI-16350, demonstrated enhanced tumor growth inhibition compared to either agent alone. Taken together, BPI-421286 is a highly potent and selective KRASG12C inhibitor, with favorable ADME properties and wide therapeutic index in pre-clinical toxicology studies. BPI-421286 is currently in Phase 1 clinical study."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS